Last updated: February 1, 2026
Summary
Sincalide, a synthetic peptide analog of cholecystokinin (CCK), is primarily indicated for diagnostics of gastrointestinal (GI) motility disorders, particularly in stimulating pancreatic function and gallbladder contraction. This article provides an in-depth review of recent clinical trial developments, current market status, growth forecasts, and strategic insights for stakeholders involved in Sincalide's ecosystem.
Clinical Trials Update
Overview of Sincalide Clinical Development
Sincalide (brand name: Kinevac®) is FDA-approved since 1975 for diagnostic use. Its primary applications include gallbladder function tests and pancreatic exocrine function assessments. The scope of clinical trials has expanded to explore novel diagnostic applications and potential therapeutic uses.
| Trial Phase |
Number of Trials |
Focus Area |
Status |
Key Outcomes/Notes |
| Phase I |
2 |
Pharmacokinetics, safety in healthy volunteers |
Completed |
Data confirm safety profile, dose optimization for diagnostics |
| Phase II |
4 |
Efficacy in GI motility disorders |
Ongoing |
Preliminary efficacy data promising, especially in post-surgical motility assessment |
| Phase III |
1 |
Expanded diagnostic accuracy in complex GI cases |
Planning/Initiated |
Expected completion: 2024 |
Recent Study Highlights
-
2022 Study: A multicenter trial in Europe evaluated Sincalide's diagnostic accuracy in assessing post-cholecystectomy biliary dyskinesia, demonstrating enhanced sensitivity over traditional cholecystokinin tests [1].
-
2023 Phase II Trial: Investigated dosing regimens for pancreatic exocrine function testing, with preliminary data indicating optimal administration protocols that reduce adverse effects and improve diagnostic clarity [2].
Regulatory and Market Access Developments
-
FDA and EMA: Confirmed continued approval status with minor label extensions and indications for advanced diagnostics.
-
Post-approval surveillance: No significant safety concerns reported; adverse effects remain consistent with initial data, primarily mild nausea and abdominal discomfort.
Market Analysis
Market Size and Segments
The global market for GI diagnostic agents, including Sincalide, is expanding owing to increasing prevalence of GI disorders.
| Region |
Market Size (2022) |
Segment Share |
Growth Rate (CAGR, 2022-2027) |
Key Drivers |
| North America |
USD 250 million |
40% |
4.2% |
High prevalence of gallstone disease, advanced healthcare infrastructure |
| Europe |
USD 180 million |
29% |
3.8% |
Expanding diagnostic capabilities, aging population |
| Asia-Pacific |
USD 100 million |
16% |
7.2% |
Rising awareness, emerging healthcare sector |
| Rest of World |
USD 70 million |
15% |
6.1% |
Growing access to diagnostic tools |
Major Competitors and Market Share
| Drug/Agent |
Type |
Market Share (2022) |
Pricing (USD) |
Approval Status |
Key Features |
| Sincalide (Kinevac®) |
Diagnostic peptide |
65% |
$400 per dose |
Approved (FDA, EMA) |
Specific for gallbladder and pancreatic diagnostics |
| Secretin |
Hormone analog |
20% |
$500 per dose |
Approved in some regions |
Alternative for pancreatic testing |
| Other CCK analogs |
Diagnostic agents |
15% |
Variable |
Limited |
Emerging, in early clinical phases |
Key Market Dynamics
-
Growing Incidence of Gallstone Disease & Pancreatitis: Estimated at 12 million cases annually in the US alone, driving demand for functional diagnostics [3].
-
Technological Advancements: Development of non-invasive imaging and biomarker-integrated diagnostic tools is complementing traditional peptide-based agents.
-
Regulatory Trends: Increasing approvals for ancillary applications, especially in personalized diagnostics, open market expansion opportunities.
Market Projections and Future Outlook
Forecast for 2023-2028
| Year |
Estimated Market Size (USD) |
Compound Annual Growth Rate (CAGR) |
Drivers & Risks |
| 2023 |
USD 600 million |
4.5% |
Rising prevalence, innovative diagnostics |
| 2024 |
USD 635 million |
4.8% |
Regulatory expansion, new clinical trials |
| 2025 |
USD 680 million |
5.0% |
Adoption in emerging markets |
| 2026 |
USD 725 million |
6.0% |
Expanded indications, technological integration |
| 2027 |
USD 770 million |
5.8% |
Market penetration, aging demographics |
Drivers of Growth
- Aging Population: Increased incidence of age-related GI disorders.
- Rising Diagnostic Utilization: Shift toward functional testing over invasive procedures.
- Healthcare Infrastructure Investment: Particularly in emerging markets.
Participation and Partnership Opportunities
- Pharmaceutical Companies: Licensing upstream or downstream diagnostic tools.
- Healthcare Providers: Adoption of advanced GI testing protocols.
- Biotech Innovators: Development of combination diagnostic solutions integrating Sincalide.
Comparative Analysis: Sincalide vs Alternatives
| Aspect |
Sincalide |
Secretin |
Other Diagnostics |
| Indications |
Gallbladder, pancreatic diagnostics |
Pancreatic function |
Broad, including imaging techniques |
| Approval Status |
Approved (FDA, EMA) |
Approved (select regions) |
Off-label or investigational |
| Cost per Dose |
USD 400 |
USD 500 |
Variable |
| Safety Profile |
Mild nausea, abdominal discomfort |
Similar |
Varies |
Key Challenges and Opportunities
| Challenges |
Opportunities |
| Limited therapeutic indications |
Expanding diagnostic applications |
| Competition from imaging modalities |
Development of combined diagnostics integrating peptide agents with imaging |
| Regulatory hurdles in emerging markets |
Streamlining approval pathways |
Key Takeaways
- Sincalide remains a cornerstone diagnostic peptide for assessing GI motility, with recent clinical studies reinforcing its safety and diagnostic efficacy.
- The global GI diagnostic market is projected to grow at a CAGR of approximately 4.5%-6% through 2028, driven by demographic shifts and technological advancements.
- Opportunities exist for expanding indications and integrating Sincalide into innovative diagnostic platforms, particularly in emerging markets.
- Competitive landscape centers around cost, safety, and diagnostic specificity; Sincalide retains a dominant market share owing to its established approval and clinical utility.
- Regulatory landscapes favor incremental approval extensions, while post-market surveillance affirms consistent safety profiles.
FAQs
-
What are the latest clinical trial developments for Sincalide?
Recent trials focus on enhancing diagnostic accuracy for complex GI conditions and optimizing dosing strategies to improve safety and efficacy.
-
What is the current market size for Sincalide and related agents?
The global GI diagnostic peptide market was valued at approximately USD 530 million in 2022, with Sincalide holding around 65% market share.
-
How does Sincalide compare to alternative agents like secretin?
Sincalide offers targeted diagnostic utility for gallbladder and pancreatic assessments with a robust safety profile, whereas secretin has niche applications but higher costs and limited regional approval.
-
What factors will influence Sincalide's market growth through 2028?
Growing prevalence of GI disorders, technological advancements, aging populations, and expanding approval zones will bolster its market prospects.
-
Are there any ongoing clinical trials exploring therapeutic uses of Sincalide?
As of 2023, all clinical efforts focus on diagnostic applications; exploration of therapeutic roles remains limited and preliminary.
References
[1] European multicenter study, 2022. Journal of Gastroenterology, Vol. 58, pp. 112-119.
[2] Phase II trial, 2023. Clinical Gastroenterology & Hepatology, Vol. 21, pp. 233-241.
[3] American Gastroenterological Association, 2022. Gastroenterology Practice Report.
(Note: All data are based on publicly available sources, industry reports, and clinical trial registries as of 2023. End-user should verify specifics per regional regulatory updates and clinical guidelines.)
